CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) announced oral and poster presentations showcasing its pacritinib program at the 64^th American Society of Hematology (ASH) Annual Meeting set for December 10-13, 2022. The oral presentation highlights pacritinib's efficacy as a potent ACVR1 inhibitor benefiting anemia in myelofibrosis patients. Key presentations include two posters on the impact of thrombocytopenia and anemia in myelofibrosis and results from the phase 3 PACIFICA study comparing pacritinib against physician's choice.

Positive

• Presentation of pacritinib's benefits at a major medical conference may enhance visibility and credibility.
• Positive findings related to anemia benefits could lead to increased investor confidence.

Negative

• None.

SEATTLE, Nov. 3, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64^th American Society of Hematology (ASH^®) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

The details of the oral presentation are as follows:

Abstract Title: Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
Abstract Number: 628
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs
Session Date: Sunday, December 11, 2022
Presentation Time: 5:15–5:30 p.m. CST/6:15–6:30 p.m. EST
Presenter: Dr. Stephen Oh

The details of the poster presentations are as follows:

Abstract Title: Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
Abstract Number: 1712
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Session Date: Saturday, December 10, 2022
Presentation Time: 5:30–7:30 p.m. CST/6:30–8:30 p.m. EST
Presenter: Dr. Jeanne Palmer
Abstract Title: PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

Abstract Number: 4316
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III 
Session Date: Monday, December 12, 202
Presentation Time: 6:00–8:00 p.m. CST/7:00–9:00 p.m. EST
Presenter: Dr. John Mascarenhas

About VONJO^® (pacritinib)
Pacritinib is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2^V617F form, IRAK1, ACVR1 (ALK2) and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Myelofibrosis is often associated with dysregulated JAK2 signaling. At clinically relevant concentrations, pacritinib does not inhibit JAK1.

VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib).

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-oral-presentation-at-the-2022-american-society-of-hematology-ash-annual-meeting-and-exposition-301667471.html

SOURCE CTI BioPharma Corp.

FAQ

What is the content of CTI BioPharma's presentation at the ASH Annual Meeting?

CTI BioPharma will present data on pacritinib, highlighting its role as an ACVR1 inhibitor with significant anemia benefits for myelofibrosis patients.

When will CTI BioPharma present at the ASH Annual Meeting?

CTI BioPharma's oral presentation is scheduled for December 11, 2022, and there will be two poster presentations on December 10 and December 12, 2022.

What is the significance of the PACIFICA study for CTI BioPharma?

The PACIFICA study is a phase 3 clinical trial evaluating pacritinib's effectiveness compared to physician's choice in patients with severe thrombocytopenia and myelofibrosis, which is crucial for its market positioning.

What does the approval of VONJO indicate for CTI BioPharma?

The approval of VONJO (pacritinib) indicates CTI BioPharma's commitment to developing targeted therapies for blood cancers and may provide a revenue stream pending further clinical validation.